Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 11/20 | 0.54 |
| ▸ | NPC1 | O15118 | 10/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216106 | 1.00 | KAT6A (0.60) | KAT6ARAB9ANPC1MAPTMEN1 | |
| SCHEMBL23158879 | 0.86 | KAT6A (0.50) | KAT6AALDH1A1GAACA12CA1 | |
| SCHEMBL6814983 | 0.86 | NPC1 (0.67) | KAT6ARAB9ANPC1MAPTMEN1 | |
| SCHEMBL13783466 | 0.85 | NPC1 (0.51) | KAT6ARAB9ANPC1MAPTMEN1 | |
| SCHEMBL4631164 | 0.84 | GAA (0.52) | KAT6ARAB9ANPC1MAPTMEN1 | |
| SCHEMBL12599766 | 0.84 | CA12 (0.47) | KAT6ARAB9ANPC1MEN1KMT2A | |
| SCHEMBL23484531 | 0.84 | CA12 (0.47) | KAT6ARAB9ANPC1MAPTMEN1 | |
| SCHEMBL22804523 | 0.84 | CA12 (0.47) | KAT6ARAB9ANPC1MAPTKDM4E | |
| SCHEMBL20932800 | 0.84 | MEN1 (0.47) | KAT6ARAB9ANPC1MAPTMEN1 | |
| SCHEMBL4672586 | 0.84 | NPC1 (0.50) | KAT6ARAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109020820-B | Preparation method of 6-bromo-2-aminonaphthalene | 杭州惠诺医药科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| WO-2025051157-A1 | PYRIDINE-2(1H)-KETONE PRMT5-MTA INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-109311813-B | Palladium-catalyzed meta-C-H functionalized universal ligands | 斯克利普斯研究院 | 2023-02-28 | — | — | CN | disclosed |
| CN-115043788-A | Trifluoromethyl oxazole-2-ketone compound and preparation method and application thereof | 南京工业大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-109020820-B | Preparation method of 6-bromo-2-aminonaphthalene | 杭州惠诺医药科技有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-106083855-B | Purine derivatives useful as Hsp90 inhibitors | 斯隆-凯特林癌症研究院 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019184089-A1 | COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳翰宇药业股份有限公司 | 2019-10-03 | — | — | WO | disclosed |
| EP-3091019-B1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3091019-A2 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Sloan Kettering Institute For Cancer Research (US) | 2016-11-09 | — | — | EP | disclosed |
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| WO-2010027280-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | disclosed |
| EP-1809603-A4 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2009-09-02 | — | — | EP | disclosed |
| US-20090182001-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
| WO-2009064908-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064913-A1 | CHIMER CONTAINING A TARGETING PORTION LINKED TO A SCISSION-ACTIVATED DUOCARMYCIN-TYPE PRODRUG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| EP-1809603-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006043839-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | XDH, HSP90B1, HSP90AA1 | KAT6A 3938/4885RAB9A 2768/4885NPC1 2300/4885 |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | KAT6A 2753/4885RAB9A 4109/4885NPC1 1707/4885 |
| US-20090182001-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, BUB1B | KAT6A 1433/4885RAB9A 2746/4885NPC1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.